EASL Roundup: Anadys, Salix, Schering
In the flurry of EASL news breaking today, shares of Anadys Pharmaceuticals Inc. plunged 42 percent in midday trading amid safety concerns about polymerase inhibitor ANA598. Meanwhile, Schering-Plough Corp. released final data from a Phase II trial of protease inhibitor boceprevir in treatment-naïve HCV patients. And Salix Pharmaceuticals Ltd. said [...]